Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology

- Presents a data-driven target combination prediction problem that aims to predict synergistic target combinations in a disease-related signaling network that can achieve the desired therapeutic effect and have minimum off-target effects.
- A solution called MASCOT that addresses this problem by leveraging machine learning-based target prioritization and Loewe additivity theory heuristics.
- A report on detailed empirical study applying MASCOT to a set of curated signaling networks that have drug-targeting data available. This study demonstrates the effectiveness and superiority of MASCOT compared to state-of-the-art network-centric target combination prediction techniques.

Given a signaling network, the target combination prediction problem aims to predict efficacious and safe target combinations for combination therapy. State-of-the-art in silico methods use Monte Carlo simulated annealing (mcsa) to modify a candidate solution stochastically, and use the Metropolis criterion to accept or reject the proposed modifications. However, such stochastic modifications ignore the impact of the choice of targets and their activities on the combination's therapeutic effect and off-target effects, which directly affect the solution quality. In this paper, we present mascot, a method that addresses this limitation by leveraging two additional heuristic criteria to minimize off-target effects and achieve synergy for candidate modification. Specifically, off-target effects measure the unintended response of a signaling network to the target combination and is often associated with toxicity. Synergy occurs when a pair of targets exerts effects that are greater than the sum of their individual effects, and is generally a beneficial strategy for maximizing effect while minimizing toxicity. mascot leverages on a machine learning-based target prioritization method which prioritizes potential targets in a given disease-associated network to select more effective targets (better therapeutic effect and/or lower off-target effects); and on Loewe additivity theory from pharmacology which assesses the non-additive effects in a combination drug treatment to select synergistic target activities. Our experimental study on two disease-related signaling networks demonstrates the superiority of mascot in comparison to existing approaches.